Immuron files FDA application for deadly C. diff infection fight
Immuron has filed a pre-investigational new drug application with the United States Food and Drug Administration for IMM-529, designed as a new therapeutic to prevent and treat recurrent Clostridioides difficile infection
https://www.marketopen.com.au/immuron-asximc-files-fda-application-for-deadly-c-diff-infection-fight/
Filter by Year:
- Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com
- Guarding Gut Health on the Go: The Travelan® Advantage
- The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!
- Biotech Daily: Dr Boreham’s Crucible: Immuron
- Immuron files FDA application for deadly C. diff infection fight
- These ASX biotechs are working with the US Department of Defense to bring new drugs to market and have a bright future ahead
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
